Aeterna Zentaris receives $2.

.. Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty Aeterna Zentaris Inc.P. . Related StoriesLilly expands existing immuno-oncology collaboration with AstraZenecaNew assistance statement on palliative treatment to be provided at 2015 Palliative Care in Oncology SymposiumResearchers discover that 26 percent of senior oncology patients use complementary or choice medicinesJuergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, We are pleased to have reached this $2.5 million milestone which is incremental to enhance perifosine, AEZS-108 and other innovative oncology compounds from our comprehensive product pipeline.To address this limitation, we performed a randomized medical trial comparing TMP-SMX and clindamycin for the treating uncomplicated skin infections at four U.S. Centers located in areas of community-associated MRSA endemicity. Methods Research Population and Design A multicenter was performed by us, prospective, randomized, double-blind clinical trial of clindamycin versus TMP-SMX for the treatment of uncomplicated skin infections.